Corcept Therapeutics Faces Securities Fraud Lawsuit Amid FDA Approval Challenges and Stock Collapse

Legal Troubles for Corcept Therapeutics

Corcept Therapeutics Incorporated is entangled in a serious securities fraud class action lawsuit that could affect numerous investors following the company's recent series of setbacks regarding FDA approvals. Kahn Swick & Foti, LLC (KSF), renowned for its expertise in securities litigation, is leading the charge on behalf of affected investors.

Background of the Case

The lawsuit, officially known as Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, pertains to events during the Class Period from October 31, 2024, to December 30, 2025. Investors who acquired shares within these dates are being urged to file lead plaintiff applications by April 21, 2026, to participate in the proceedings. Former Attorney General of Louisiana, Charles C. Foti, Jr., is involved with KSF, urging investors to seek recovery for substantial losses.

The allegations focus on Corcept's failure to disclose critical material information about its lead drug candidate, relacorilant. During the Class Period, the company asserted to investors that there was a high likelihood the FDA would grant approval for relacorilant after its New Drug Application (NDA) was submitted. However, on December 31, 2025, the company revealed that the FDA issued a Complete Response Letter (CRL), indicating its inability to confirm a favorable benefit-risk assessment without further evidence of effectiveness from Corcept.

Following this disclosure, Corcept's stock price took a dramatic hit, dropping from $70.20 to a staggering $34.80 in a single day—an overall decline of 50.4%. This sharp decline has understandably alarmed shareholders and raised questions regarding the company’s disclosures leading up to the fallout.

Understanding the Implications

The consequences of this lawsuit are significant, not just for Corcept and its executives but also for shareholders who feel misled about the potential for the company's drug candidate. Legal experts warn that investors must act quickly to assert their rights; failure to do so may mean missing out on a potential recovery opportunity.

Kahn Swick & Foti, LLC believes that through this class action, investors may have a path to recover economic losses stemming from undeclared risks. Investors are advised without any obligation to connect with KSF for a consultation to discuss their individual situations, including the possibility of serving as lead plaintiffs in this case.

Despite the current troubles, Corcept remains operational, and active discussions about relacorilant and future product pipelines continue amidst growing scrutiny.

Kahn Swick & Foti: Who They Are

As a premier boutique law firm focused on securities litigation, KSF has established a strong reputation within the legal community. The firm ranks among the top 10 nationally in terms of settlement values, focusing on the rights of public and private institutional investors as well as retail investors who may be victims of corporate fraud or mismanagement.

Those impacted by the stock decline are encouraged to familiarize themselves with both the potential legal ramifications and their options moving forward. With a court filing deadline approaching, swift action may provide affected investors a chance at financial recovery.

For more information, investors can reach out to Lewis Kahn, Managing Partner at KSF, either via phone or email, or visit their website for additional details about the case and how to proceed.

Contact Information:
Kahn Swick & Foti, LLC
Lewis Kahn
Phone: 1-877-515-1850
Email: [email protected]
Website: www.ksfcounsel.com

For investors facing challenges, knowledge is power, and advocacy is available. Engage with the desired legal guidance through this turbulent period for Corcept Therapeutics.